UNSPSC 51102910: Dihydroartemisinin/Piperaquine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AP101. This VA Drug Class (AP101) classifies this compound as belonging to the group ANTIMALARIALS.

UNSPSC 51102910 Dihydroartemisinin/Piperaquine, a Commodity code, shows a significant mismatch between its nominal scope and actual recent state and local procurement activity. The code nominally addresses a specific antimalarial pharmaceutical combination, yet recent opportunities posted under this code cover naloxone kits, generic multi-source pharmaceuticals and OTC products, medical and first aid supplies for emergency response, and therapeutic pharmacy initiatives — none of which are dihydroartemisinin/piperaquine formulations. State and local buyers appear to be using this code as a catch-all for pharmaceutical procurement rather than for the narrow product category the code name implies, suggesting either broad tagging practices or catalog misclassification within state procurement systems.

The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), municipal fire departments (City of Tampa), and multi-state cooperative purchasing alliances (MMCAP, Minnesota Department of Administration). Geographic activity spans Florida, Texas, Minnesota, and Oregon. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a due date of July 26, 2023, under IFB 60459723LAS; the Texas Health and Human Services Commission's RFI for direct-to-manufacturer prescription program capabilities posted April 3, 2026; the City of Tampa's ITB for medical and first aid supplies for the Fire Department Rescue Division with a due date of March 13, 2026 and an estimated contract value of $700,000.00, designated as a sheltered market for certified Small Local Business Enterprises with a 5 percent bid discount; and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, requiring supply through three authorized wholesalers. Buyers soliciting under this code typically require FDA compliance, current Good Manufacturing Practices certification, Drug Supply Chain Security Act adherence, and compliance with expiration-date requirements ranging from six months to nine months of shelf life at delivery.